A Phase 1 Study of OT-82 in Patients With Relapsed or Refractory Lymphoma
Phase of Trial: Phase I
Latest Information Update: 16 Oct 2019
Price : $35 *
At a glance
- Drugs OT-82 (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors OncoTartis
- 05 Sep 2019 Planned primary completion date changed from 1 Apr 2020 to 1 Apr 2021.
- 05 Sep 2019 Status changed from not yet recruiting to recruiting.
- 17 Apr 2019 Status changed from planning to not yet recruiting.